Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Pathol. 2002 Dec;161(6):1991-6.

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.

Author information

  • 1L235 Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA. mrijn@stanford.edu

Erratum in

  • Am J Pathol. 2003 Jul;163(1):377.

Abstract

While several prognostic factors have been identified in breast carcinoma, the clinical outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide difficult treatment decisions. In a previous study of 78 breast carcinoma specimens, we noted an association between poor clinical outcome and the expression of cytokeratin 17 and/or cytokeratin 5 mRNAs. Here we describe the results of immunohistochemistry studies using monoclonal antibodies against these markers to analyze more than 600 paraffin-embedded breast tumors in tissue microarrays. We found that expression of cytokeratin 17 and/or cytokeratin 5/6 in tumor cells was associated with a poor clinical outcome. Moreover, multivariate analysis showed that in node-negative breast carcinoma, expression of these cytokeratins was a prognostic factor independent of tumor size and tumor grade.

PMID:
12466114
[PubMed - indexed for MEDLINE]
PMCID:
PMC1850928
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk